Turmeric and Curcumin
Turmeric is the ground rhizome of Curcuma longa, curcumin its yellow colouring; human studies show improvements in metabolism, inflammation and joints.
We evaluated 375 human studies on Turmeric and Curcumin, including 242 randomised controlled trials and 101 meta-analyses or systematic reviews; the controlled studies include 16,291 participants in total. As of 4 October 2026.
1. What Is Turmeric and Curcumin? Occurrence, Origin and Forms
Turmeric is the dried and ground rhizome (rootstock) of Curcuma longa, a plant in the ginger family. Curcumin is the yellow pigment of the rhizome and belongs to the group of curcuminoids. Turmeric is traditionally used as a spice and colouring.
Curcuma longa is cultivated in tropical regions of Asia; the part used is the underground rhizome, where the curcuminoids are located. The plant needs a warm, humid climate and is propagated through the rhizome.
For the spice and for extracts the rhizome is dried and ground; curcumin extracts are made from that powder and adjusted to a defined curcuminoid content. Studies examine, among other forms, the powder, extracts, preparations with additives meant to improve absorption, and individual curcuminoids.
Forms and Preparations Studied
- Turmeric powder from the ground rhizome
- Curcuminoid-rich extract
- Curcumin with piperine from black pepper
- Curcumin in phytosome form
- Individual curcuminoids such as demethoxycurcumin and bisdemethoxycurcumin
- Hydrogenated curcumin (tetrahydrocurcumin)
Not covered on this page:
- Other Curcuma species such as zedoary (Curcuma zedoaria) and Javanese turmeric (Curcuma xanthorrhiza)
- Other ginger-family plants such as ginger (Zingiber officinale) and galangal (Alpinia)
- The essential oil obtained from turmeric, which contains no curcuminoids
2. What Does Turmeric and Curcumin Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Metabolism and blood values | mostly improved | high | 24 meta-analyses · 90 controlled · 16 other | 5,919 |
| Inflammation-related conditions | mostly improved | high | 17 meta-analyses · 94 controlled · 22 other | 6,429 |
| Joints and the musculoskeletal system | mostly improved | high | 16 meta-analyses · 43 controlled · 20 other | 3,339 |
| Absorption in the body | mostly improved | high | 1 meta-analyses · 28 controlled · 7 other | 1,077 |
| Digestion | mostly improved | high | 4 meta-analyses · 13 controlled · 2 other | 511 |
| Tolerability and safety | mostly no difference | high | 2 meta-analyses · 13 controlled · 89 other | 1,732 |
| Other investigations | mixed | high | 22 meta-analyses · 127 controlled · 34 other | 8,900 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Turmeric and Curcumin, Metabolism and Blood Values: Human Studies
For metabolism and blood values, curcumin showed improvements in fasting blood glucose 4822394387 and HbA1c 8224387106110 in several controlled studies. Insulin resistance also improved in several controlled studies 46970106140316, as did liver enzymes 44467168220 and markers of oxidative stress 39112140174. Curcuminoid-rich extracts, curcumin in phytosome form and partly unspecified preparations were investigated; the robustness is high, as 24 meta-analyses and 90 controlled studies with a total of 5919 participants are available. A randomised controlled study in healthy older people found elevated blood glucose under lipidated curcumin 170. Many studies do not precisely state form, curcuminoid content and duration of administration, and information on manufacturer funding is largely missing.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Wang et al. 2025 | meta-analysis · 30,133 participants | Dietary supplements, including curcumin; vs. Control groups of included randomized trials | Fasting glucose: improved (SMD = -3.43) |
| 3 Wan et al. 2024 | meta-analysis · 17,126 participants | Polyphenol antioxidant supplements, including curcumin; vs. Control groups of the included randomized trials | indicators of glucose metabolism: improved |
| 4 Jafari et al. 2024 | meta-analysis · 7,216 participants | Curcuma longa L. (form not specified in abstract); vs. Placebo | Fasting blood sugar: improved; High-density lipoprotein: improved; Weight: improved |
| 8 Amgain et al. 2025 | meta-analysis · 3,706 participants | Curcumin (turmeric extract); exact form not reported; vs. Placebo or control (RCTs within reviews) | Fasting blood glucose: improved (MD = - 6.30 mg/dL; 95% CI: - 9.33, - 3.27); HbA1c: improved (MD = - 0.31%; 95% CI: - 0.57, - 0.05); LDL cholesterol: improved (MD = - 5.95 mg/dL; 95% CI: - 9.43, - 2.47) |
| 13 Ranneh et al. 2024 | systematic review · 1,840 participants | Dietary polyphenol supplementation, including turmeric and curcumin; vs. Control groups of the included RCTs | liver enzymes: improved; lipid profile: improved; insulin resistance: improved |
| 19 Xie et al. 2026 | meta-analysis · 1,502 participants | Dietary polyphenols, including curcuminoids, flavonoids, stilbenes; Recommendation: long-term over 8 weeks; vs. Polyphenol supplementation versus control | Serum uric acid: no difference (non-significant effects); Serum uric acid (flavonoids/anthocyanins): improved (significantly reduced SUA levels) |
| 22 Mokgalaboni et al. 2024 | meta-analysis · 1,382 participants | Curcumin supplementation (form not specified); vs. Placebo | Fasting blood glucose: improved (MD = -11.48 mg/dL, 95%CI (-14.26, -8.70), p < 0.01); Glycated hemoglobin: improved (MD = -0.54%, 95%CI (-0.73, -0.35), p < 0.01) |
| 23 Bahari et al. 2026 | systematic review · 1,303 participants | Curcumin/turmeric supplementation; vs. Placebo or control | Serum creatinine: no difference (WMD: -0.01 mg/dL, 95% CI: -0.03 to 0.01, p = 0.519); Blood urea nitrogen (BUN): no difference (WMD: -0.41 mg/dL, 95% CI: -3.15 to 2.33, p = 0.769); Uric acid: unclear (WMD: -1.46 mg/dL, 95% CI: -2.93 to 0.02, p = 0.053) |
Further studies in this area: 32 34 39 40 42 43 44 45 47 58 59 60 64 65 67 68 69 70 71 73 74 75 76 81 86 87 92 98 106 110 111 112 118 125 134 135 137 138 139 140 143 145 146 147 148 151 157 161 162 164 165 168 169 170 172 173 174 176 177 178 179 180 181 183 187 189 191 192 194 197 199 200 205 208 209 214 216 219 220 221 222 224 226 235 239 240 243 244 245 246 247 252 254 256 258 262 264 265 270 273 276 277 281 284 285 291 294 307 308 309 316 322 324 326 327 331 338 345 364 366 368 369
Turmeric and Curcumin and Inflammation-Related Conditions: Human Studies
In inflammation-related complaints, curcumin showed improvements in C-reactive protein in several controlled studies and meta-analyses 4515223953. Tumor necrosis factor-alpha, a messenger substance of inflammation, also decreased more strongly than under control in several studies 51539111112159. Likewise, the erythrocyte sedimentation rate 5372119190198279 and the inflammatory messengers interleukin-6 5111112159174 and interleukin-1 beta 111112174 improved. As an adjunct to periodontal treatment, curcumin lowered the gingival index more strongly than the treatment alone 35250; in rheumatoid arthritis, the rheumatoid factor decreased more strongly than under control 72279. A meta-analysis on knee osteoarthritis found no difference from placebo for erythrocyte sedimentation rate and interleukin-6 15. Two further controlled studies also saw no difference in the inflammatory markers 247323. Curcumin, curcuminoid-rich extracts, turmeric powder, curcumin with piperine, and phytosome forms were investigated. Findings from a meta-analysis of various polyphenols in rheumatoid arthritis cannot be attributed to curcumin alone 7. The findings come predominantly from small to medium-sized studies of varying form, dose, and duration, which limits the informative value.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Jafari et al. 2024 | meta-analysis · 7,216 participants | Curcuma longa L. (form not specified in abstract); vs. Placebo | C-reactive protein: improved; Glutathione: improved; Superoxide dismutase: improved |
| 5 Naghsh et al. 2023 | meta-analysis · 5,870 participants | Curcumin supplementation; vs. Placebo or control | C-reactive protein (CRP): improved (ES = -0.74; 95% CI: -1.11, -0.37, p < 0.001); Interleukin-6 (IL-6): improved (ES = -1.07; 95% CI: -1.71, -0.44, p < 0.001); Tumour necrosis factor α (TNF-α): improved (ES: -1.92, 95% CI: -2.64, -1.19, p < 0.0) |
| 7 Long et al. 2023 | meta-analysis · 3,852 participants | Curcumin among 14 other polyphenols (mixture); vs. Placebo or control, pooled across 47 RCTs | C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR): improved; Oxidative stress levels: improved |
| 11 Zeng et al. 2022 | meta-analysis · 2,396 participants | Curcumin and Curcuma longa extract; 120 mg to 1500 mg; 4 to 36 weeks; vs. randomized controlled trials (control groups not specified) | inflammation severity: improved |
| 13 Ranneh et al. 2024 | systematic review · 1,840 participants | Dietary polyphenol supplementation, including turmeric and curcumin; vs. Control groups of the included RCTs | inflammatory cytokines: improved |
| 15 Hsueh et al. 2025 | meta-analysis · 1,705 participants | Curcumin (form not specified); vs. Placebo or control group | C-reactive protein (CRP): improved (SMD = -0.906, 95% CI = -1.543 ~ -0.269, P value = 0.005); Tumor necrosis factor-alpha (TNF-alpha): improved (SMD = -0.921, 95% CI = -1.817 ~ -0.026, P value = 0.044); Erythrocyte sedimentation rate (ESR): no difference (SMD = -0.064, 95% CI = -0.064 ~ 0.541, P value = 0.836) |
| 20 Chen et al. 2025 | meta-analysis · 1,463 participants | Dietary supplements including curcumin; vs. Network meta-analysis comparing supplements | Interleukin-22: improved (curcumin reduced IL-22) |
| 22 Mokgalaboni et al. 2024 | meta-analysis · 1,382 participants | Curcumin supplementation (form not specified); vs. Placebo | C-Reactive Protein: improved (SMD = -0.59, 95%CI (-1.11, -0.07), p = 0.03) |
Further studies in this area: 25 31 35 39 47 52 53 54 55 57 59 66 68 70 72 75 76 81 83 102 107 110 111 112 114 117 118 119 123 139 140 141 145 146 147 153 154 156 159 162 164 165 167 171 172 174 176 177 179 180 185 186 187 188 190 191 195 196 198 200 201 204 205 206 208 209 211 213 216 217 218 219 221 224 228 231 240 241 244 247 250 251 254 256 260 261 262 264 266 269 274 279 287 291 293 294 298 304 307 309 313 314 315 316 318 320 323 325 330 331 333 336 340 350 354 355 356 357 361 362 363 364 368 369 370
Turmeric and Curcumin, Joints and the Musculoskeletal System: Human Studies
In joint and movement complaints, curcumin showed improvements in pain intensity in several controlled studies, predominantly in knee osteoarthritis 1124375380101. WOMAC scores 680101206 and KOOS pain scores 123202 also improved more than under placebo. Several controlled studies also found better function scores than in the comparison group 93229309 and, in rheumatoid arthritis, lower disease activity 537291279. After unaccustomed exertion, muscle soreness recovered faster under a turmeric preparation than under placebo, and muscle strength declined less 242. Investigated were predominantly curcuminoid-rich extracts, partly in bioavailability-improved or water-dispersible forms, as well as topical curcumin gel and hydrogenated curcumin 202229279309333. Two controlled studies found no difference from ibuprofen 104 or paracetamol 336, respectively, in pain and function. Disease activity in rheumatoid arthritis and lupus 52, inflammatory markers and synovitis in knee osteoarthritis 323, and performance tests under curcumin gel 202 remained without difference from the control. The findings come partly from combination preparations with Boswellia serrata, NSAIDs or chondroprotective agents and cannot be attributed to curcumin alone 12161718. The evidence is strong, but many studies are small and short, the forms and additives are inconsistent, and information on manufacturer funding is largely missing.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 6 Zhang et al. 2025 | meta-analysis · 4,599 participants | Curcumin as a nutritional supplement; vs. Placebo | WOMAC function: improved; WOMAC pain, stiffness, VAS pain: unclear |
| 7 Long et al. 2023 | meta-analysis · 3,852 participants | Curcumin among 14 other polyphenols (mixture); vs. Placebo or control, pooled across 47 RCTs | Disease activity score for 28 joints (DAS28): improved |
| 11 Zeng et al. 2022 | meta-analysis · 2,396 participants | Curcumin and Curcuma longa extract; 120 mg to 1500 mg; 4 to 36 weeks; vs. randomized controlled trials (control groups not specified) | pain levels: improved |
| 12 Zhao et al. 2024 | meta-analysis · 2,175 participants | Curcumin alone or curcumin plus NSAIDs/chondroprotective agents; vs. placebo, NSAIDs, curcumin+NSAIDs, curcumin+chondroprotective agents | VAS pain score: improved (MD = -1.63, 95% CI: -2.91 to -0.45); total WOMAC score: improved (MD = -18.85, 95% CI: -29.53 to -8.76); use of rescue medication: improved (OR = 0.17, 95% CI: 0.08 to 0.36) |
| 14 Del et al. 2017 | meta-analysis · 1,741 participants | Oral herbal medicines, including Curcuma longa; vs. Placebo or control | Pain and physical function: no difference |
| 16 Inprasit et al. 2026 | meta-analysis · 1,633 participants | Curcuma longa (CL), Boswellia serrata (BS), and mixed formulation; vs. Placebo or other intervention groups | Pain (VAS): improved (SMD: -2.82; 95 %CI: -5.30 to -0.33); WOMAC pain, stiffness, and knee function: improved |
| 17 Zeng et al. 2021 | systematic review · 1,621 participants | Curcuma longa extract and curcumin supplements; Recommended: more than 12 weeks; vs. Placebo, NSAIDs, NSAIDs plus curcumin | VAS pain: improved; WOMAC pain: improved; WOMAC function: improved |
| 18 Wan et al. 2022 | systematic review · 1,533 participants | Curcuminoid formulations alone or with conventional therapy; vs. NSAIDs or chondroitin sulfate/glucosamine alone | VAS pain: no difference; total WOMAC score: no difference; WOMAC pain/stiffness/physical function: no difference |
Further studies in this area: 24 27 29 30 31 36 37 38 52 53 61 72 76 77 79 80 90 91 93 97 99 100 101 104 108 109 115 116 117 122 123 141 142 143 149 153 154 160 163 171 179 188 201 202 206 219 225 229 232 234 242 245 256 275 279 280 285 287 293 309 323 328 333 336 337 343 347 348 353 370 372
Turmeric and Curcumin and Absorption in the Body: Human Studies
Specially prepared forms improved absorption in several controlled studies: micellar, water-soluble, and newly developed preparations achieved higher systemic exposure than conventional curcumin or standard extract 278294299. The peak plasma concentrations were also higher with these preparations 278294299. Curcumin packaged in fat or water particles (liposomal, nanoemulsified, micellar) was measurable in the blood 233245247. An overview mainly of animal and laboratory studies suggests that curcumin is better absorbed in tiny carrier particles (nanocarriers). The findings apply to the respective form investigated — curcuminoid-rich extracts, phytosome and micellar preparations, and ground turmeric rhizome powder — and not to curcumin in general. No difference was found in free curcuminoids between five preparations, between piperine combination and standard extract 271, or in plasma levels after three doses of turmeric powder 305. Most studies were small and investigated healthy volunteers over a short period; the informative value is therefore limited despite the high number of controlled studies.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 73 Al-Makhmari et al. 2025 | systematic review | Curcumin (Curcuma longa), form and dose not reported; vs. other herbs and controls, not detailed | bioavailability: unclear (its bioavailability remains a challenge) |
| 79 Sato et al. 2025 | systematic review | Curcumin or natural derivatives in nanocarrier systems; vs. Free curcumin versus encapsulated curcumin | Solubility, bioavailability and stability: improved |
| 116 Bhat et al. 2023 | randomised controlled · 200 participants | Oral curcumin 1 g with piperine 5 mg; 1 g curcumin plus 5 mg piperine twice daily; 52 weeks; vs. Placebo, concurrent csDMARD tapering | Correlation of serum curcuminoid levels with flares: no difference (adjusted HR = 0.99 (95% CI: 0.97-1.0)) |
| 126 Wightman et al. 2023 | randomised controlled · 128 participants | Multi-ingredient herbal supplement with turmeric whole powder and Turmeric Wholistic™ extract; 90 days (12 weeks); vs. Placebo, randomized, parallel groups | tyrosine in urinary metabolome: improved |
| 153 Majumdar et al. 2025 | randomised controlled · 90 participants | CL20192 capsule: Boswellia serrata and Curcuma longa extracts; 300 mg once daily; 90 days; vs. Placebo capsule | Serum levels of boswellic acids and curcuminoids: improved |
| 158 Panahi et al. 2016 | randomised controlled · 89 participants | Curcuminoids (1500 mg/day) plus piperine (15 mg/day); 1500 mg curcuminoids + 15 mg piperine daily; 4 weeks; vs. Placebo, double-blind, randomized | Serum GSH levels: improved (p < 0.001); Serum MDA levels: improved (p < 0.001) |
| 162 Azhdari et al. 2026 | randomised controlled · 84 participants | Curcumin 500 mg/day, alone or with zinc 30 mg/day; Curcumin 500 mg/day; zinc 30 mg/day; 90 days; vs. Placebo, four groups (curcumin, zinc, curcumin+zinc, placebo) | serum zinc: improved (p=0.001); urinary zinc: improved (p=0.04) |
| 214 Pandaran et al. 2016 | randomised controlled · 60 participants | CurQfen (curcumagalactomannoside), natural curcumin with fenugreek fiber; 500 mg twice daily; single dose 500 mg once daily; 30 days; vs. standard curcumin and placebo | free curcuminoids bioavailability, single dose: improved (30.7-fold); free curcuminoids bioavailability, repeated dose: improved (39.1-fold) |
Further studies in this area: 233 243 245 247 263 271 274 278 290 292 294 296 297 299 300 301 305 311 318 332 342 346 351 354 357 360 362 364
Turmeric and Curcumin and Digestion: Human Studies
In women with severe obesity, curcumin alleviated gastrointestinal complaints such as belching and constipation more strongly than placebo 265; in children with autism, complaints and fecal calprotectin decreased 198. In ulcerative colitis, a meta-analysis and two reviews of small studies found evidence of a benefit of curcumin, especially as an adjunct to standard therapy 919496. A review saw possible effectiveness in irritable bowel syndrome and chronic inflammatory bowel diseases 85. In irritable bowel syndrome, a meta-analysis found a favorable but not confirmed effect 51, a small randomized study found no difference in gastrointestinal symptoms 291. In hepatic steatosis and liver stiffness, curcumin improved the values in a randomized controlled study 174, and in periodontitis, curcuminoid gel or curcumin gel improved the periodontal parameters 269304. The findings are based predominantly on small studies of short duration and without information on manufacturer funding; the forms investigated ranged from curcuminoid-rich extract to curcumin with piperine and phytosome form to combination preparations with other substances. Findings from combination preparations are not due to curcumin alone: an herbal preparation with turmeric lowered Sutterella and constipation 126, curcumin with piperine the NAFLD severity 173, a curcumin-boswellia phytosome bloating and abdominal pain 189.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 51 Ng et al. 2018 | meta-analysis · 326 participants | Curcumin (preparation not specified); vs. Control group in randomized controlled trials | IBS symptom severity from baseline: no difference (pooled standardized mean difference from baseline IBS severity rating -0.466, 95% CI: -1.113 to 0.182, p = 0.158) |
| 85 Thavorn et al. 2024 | systematic review | Turmeric (form and curcuminoid content not reported); vs. Randomized controlled trials and comparative observational studies | Efficacy in IBD or IBS: improved; Efficacy in other digestive disorders: unclear |
| 91 Zeng et al. 2022 | meta-analysis | Curcumin and Curcuma longa extract; vs. Placebo or control in included RCTs | Clinical or laboratory improvement in ulcerative colitis: improved |
| 94 Coelho et al. 2020 | systematic review | Curcumin as complementary therapy; vs. Placebo-controlled RCTs | Maintenance of remission in ulcerative colitis: improved; Remission in Crohn's disease: unclear |
| 96 Holleran et al. 2020 | systematic review | Curcumin as a herbal medicine; vs. Placebo in double-blind randomised controlled trials | Evidence of efficacy in ulcerative colitis: improved |
| 126 Wightman et al. 2023 | randomised controlled · 128 participants | Multi-ingredient herbal supplement with turmeric whole powder and Turmeric Wholistic™ extract; 90 days (12 weeks); vs. Placebo, randomized, parallel groups | Sutterella in gut microbiome and constipation: improved |
| 173 Mirhafez et al. 2021 | randomised controlled · 79 participants | Curcumin plus piperine; 500 mg/day curcumin; 2 months; vs. Placebo, both groups received diet and exercise advice | NAFLD severity: improved (p = 0.04) |
| 174 Yaikwawong et al. 2025 | randomised controlled · 78 participants | Curcumin (bioactive polyphenol from turmeric); 1500 mg/day; 12 months; vs. placebo, randomized, double-blind | hepatic steatosis: improved; liver stiffness: improved |
Further studies in this area: 189 198 265 269 291 302 304 308 314 341 359
Turmeric and Curcumin, Tolerability and Safety: Human Studies
In this area, 13 controlled studies and 2 meta-analyses with a total of 1732 participants were evaluated for the tolerability of turmeric and curcumin. Several controlled studies and reviews described curcuminoids, curcumin in phytosome form and hydrogenated curcuminoids as well tolerated 8589159228279. Liver and kidney values remained unremarkable under curcumin 110, liver enzymes remained unchanged under micellar curcuminoids 247, and laboratory values as well as vital signs did not differ from placebo 203. Meta-analyses and reviews found no increase in adverse events under curcumin 6505193; in a large randomized study over two years, side effects were rare and mild 103. A meta-analysis on curcumin and Curcuma longa extract in various forms of arthritis found no differences in safety endpoints 11. A meta-analysis on Curcuma longa, also as a mixture with Boswellia serrata, found no differences in adverse events 16. A systematic review on Curcuma longa extract and curcumin, partly as a mixture with NSAIDs, reported no differences in adverse events compared with placebo 17. A systematic review found no differences between curcuminoid formulations and NSAIDs in satisfaction, treatment adherence and rescue medication 18. The findings apply to the forms studied — powder, extract, phytosome form and individual substances — and, because of the mostly short study duration and the heterogeneous preparations, can be transferred to long-term use only to a limited extent.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 6 Zhang et al. 2025 | meta-analysis · 4,599 participants | Curcumin as a nutritional supplement; vs. Placebo | Adverse events |
| 7 Long et al. 2023 | meta-analysis · 3,852 participants | Curcumin among 14 other polyphenols (mixture); vs. Placebo or control, pooled across 47 RCTs | Adverse events |
| 9 Gutsche et al. 2025 | systematic review · 2,580 participants | Curcumin as complementary therapy, topical or systemic; vs. Control groups of included RCTs | Vomiting: worsened |
| 11 Zeng et al. 2022 | meta-analysis · 2,396 participants | Curcumin and Curcuma longa extract; 120 mg to 1500 mg; 4 to 36 weeks; vs. randomized controlled trials (control groups not specified) | safety |
| 12 Zhao et al. 2024 | meta-analysis · 2,175 participants | Curcumin alone or curcumin plus NSAIDs/chondroprotective agents; vs. placebo, NSAIDs, curcumin+NSAIDs, curcumin+chondroprotective agents | incidence of adverse reactions (OR = 0.51, 95% CI: 0.25 to 0.94) |
| 16 Inprasit et al. 2026 | meta-analysis · 1,633 participants | Curcuma longa (CL), Boswellia serrata (BS), and mixed formulation; vs. Placebo or other intervention groups | Adverse events |
| 17 Zeng et al. 2021 | systematic review · 1,621 participants | Curcuma longa extract and curcumin supplements; Recommended: more than 12 weeks; vs. Placebo, NSAIDs, NSAIDs plus curcumin | Adverse events vs. placebo; Adverse events vs. NSAIDs; Adverse events with curcumin plus NSAIDs |
| 18 Wan et al. 2022 | systematic review · 1,533 participants | Curcuminoid formulations alone or with conventional therapy; vs. NSAIDs or chondroitin sulfate/glucosamine alone | satisfaction index, global assessment, compliance, rescue medication: no difference |
Further studies in this area: 21 24 29 33 38 49 50 51 59 77 78 85 89 90 93 94 99 102 103 104 110 115 116 117 120 122 123 125 129 133 135 142 150 151 152 153 154 159 161 163 175 180 182 185 196 202 203 206 208 209 210 224 225 228 229 232 233 234 236 245 247 248 258 263 268 271 274 275 278 279 282 283 284 285 288 289 290 296 297 301 303 306 309 328 333 336 337 347 348 349 350 351 352 361 362 370
Turmeric and Curcumin: Further Outcomes in Studies
For cognition, several studies found improvements 464957129170, while individual controlled studies showed no difference 49263. For depression 265056112244 and anxiety 2650, several studies also found improvements. The forms ranged from turmeric powder to phytosome; mixed preparations with resveratrol or green tea extract cannot be attributed to curcumin alone 13. The robustness is overall high, but the heterogeneity of the preparations, formulations and endpoints does not allow a uniform statement; it remains open which form and which curcuminoid content are effective for which endpoint.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 An et al. 2022 | meta-analysis · 883,627 participants | Curcumin as micronutrient supplement; vs. Placebo or control | Cardiovascular risk factors: improved (moderate- to high-quality evidence for reducing CVD risk factors) |
| 9 Gutsche et al. 2025 | systematic review · 2,580 participants | Curcumin as complementary therapy, topical or systemic; vs. Control groups of included RCTs | Oral mucositis: improved; Weight loss: improved; Oral and skin symptoms, pain, body composition, survival, disease progression: unclear |
| 10 Zeng et al. 2025 | meta-analysis · 2,481 participants | Nanocurcumin compared with other nutritional supplements; vs. other supplements, e.g. BSO, probiotics, vitamin D | FEV1% (lung function): improved (MD=13, 95% CI (7.7, 18)); FEV1/FVC: improved (MD=12, 95% CI (4.6, 19), p<0.05) |
| 13 Ranneh et al. 2024 | systematic review · 1,840 participants | Dietary polyphenol supplementation, including turmeric and curcumin; vs. Control groups of the included RCTs | NAFLD score: improved |
| 18 Wan et al. 2022 | systematic review · 1,533 participants | Curcuminoid formulations alone or with conventional therapy; vs. NSAIDs or chondroitin sulfate/glucosamine alone | Karnofsky Performance Scale score vs. chondroitin sulfate/glucosamine: no difference |
| 21 Sawangjit et al. 2025 | meta-analysis · 1,407 participants | Turmeric, mostly nano-curcumin, as adjunct to standard care; Nano-curcumin 160-240 mg/day; vs. Placebo or standard care | All-cause mortality: improved (RR = 0.39; 95 % CI: 0.23-0.67); Need for intubation/mechanical ventilation: improved (RR = 0.35; 95 % CI: 0.17-0.72); Clinical deterioration: improved (RR=0.36; 95 % CI: 0.22-0.59) |
| 25 Indriyani et al. 2025 | systematic review · 1,244 participants | Curcumin, various formulations; vs. randomized controlled trials (control not specified) | antioxidant, collagenase-inhibiting, antifungal and wound-healing properties: improved |
| 26 Yuan et al. 2025 | systematic review · 1,123 participants | Curcumin from Curcuma longa, various formulations; varied, not reported in abstract; vs. placebo or control | Depressive symptoms (SMD): improved (SMD: -0.65, P = 0.01, 95% CI: -1.16 to -0.13); Anxiety symptoms (SMD): improved (SMD: -0.22, P = 0.01, 95% CI: -0.40 to -0.05) |
Further studies in this area: 28 32 41 44 45 46 47 48 49 50 54 56 57 59 62 63 66 70 75 76 78 81 82 83 84 88 89 91 95 102 103 105 107 112 113 114 120 121 122 124 126 127 128 129 130 131 132 133 136 142 143 144 149 150 151 152 153 155 158 159 164 165 166 168 170 175 176 179 181 182 184 185 187 189 190 191 193 196 198 199 200 201 205 207 208 209 210 212 213 214 215 216 219 220 221 223 224 227 228 229 230 237 238 239 240 241 244 246 248 249 251 253 254 255 256 257 259 261 263 267 268 272 273 274 280 281 282 283 284 285 286 287 288 289 293 295 303 305 306 307 310 312 313 314 317 318 319 321 322 325 327 329 334 335 339 344 347 348 349 350 351 353 354 355 356 357 358 360 361 362 363 365 367 371 373
4. How Is Turmeric and Curcumin Dosed? Preparation, Dose and Duration in Studies
The studies used ground turmeric rhizome powder, curcuminoid-rich extracts, curcumin with piperine from black pepper, curcumin in phytosome form as well as individual curcuminoids and hydrogenated curcumin. Some of the investigations tested mixed preparations with other polyphenols, Boswellia serrata or NSAIDs, whose findings cannot be attributed to curcumin alone. Form, curcuminoid content and duration of administration were not precisely stated in many studies.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| oral curcumin (turmeric extract, exact composition not stated) | 2000 mg per dose, 8 doses over 4 days | 4 days perioperative | 102 |
| Oral submicron-powdered curcumin (Theracurmin®) | 180 mg twice daily | 2 years | 103 |
| Curcuma domestica extract (1,500 mg/day) | 1,500 mg/day | 4 weeks | 104 |
| commercially available curcumin 500 mg orally | 500 mg curcumin daily | 90 days treatment, then 3 months post-treatment follow-up | 105 |
| Curcumin extract (Curcuma longa) | 1500 mg/day | 12 months | 106 |
| SinaCurcumin™ nano-curcumin | 240 mg daily | 3 days pre-op plus 4 post-op days | 107 |
| turmeric-Boswellia extract (TBE), 1,000 mg | 1,000 mg TBE | 6 hours | 108 |
| TBF (Rhuleave-K): turmeric and boswellia extracts in sesame oil | single dose of 1000 mg TBF | single dose, follow-up up to 6 hours | 109 |
| Curcumin 1500 mg daily | 1500 mg/day | 12 months | 110 |
| Curcumin (from turmeric root) | — | 12 months | 111 |
| Curcumin supplement | — | 12 months | 112 |
| PMSoff supplement containing turmeric among 11 ingredients | — | 2 months | 113 |
| BV-4051, Ayurvedic polyherbal tablet with Ashwagandha, Boswellia, Ginger and Turmeric | — | 14 days | 114 |
| CuraMed (curcuminoid extract with turmeric oil) or Curamin (plus boswellic acid) | 500 mg capsule three times daily (333 mg curcuminoids; 350 mg curcuminoids + 150 mg boswellic acid) | 12 weeks | 115 |
| Oral curcumin 1 g with piperine 5 mg | 1 g curcumin plus 5 mg piperine twice daily | 52 weeks | 116 |
5. Is Turmeric and Curcumin Safe? Side Effects in Studies
Curcumin was well tolerated in most studies 5089159228. Under a Curcuma domestica extract, abdominal pain occurred less often than under ibuprofen 104, other studies reported more gastrointestinal complaints under curcumin 949263275. As an infusion, liposomal curcumin temporarily changed the shape of red blood cells at higher doses 233.
| Study | Reported side effects |
|---|---|
| 6 Zhang et al. 2025 | No increase in adverse events versus placebo |
| 7 Long et al. 2023 | Adding polyphenols did not increase adverse events |
| 9 Gutsche et al. 2025 | One study reported significantly more vomiting in the curcumin group |
| 11 Zeng et al. 2022 | Safe in all studies; no further details |
| 12 Zhao et al. 2024 | curcumin and curcumin+NSAIDs reduced adverse reactions versus NSAIDs |
| 14 Del et al. 2017 | Adverse events as secondary outcome, no numbers reported |
| 16 Inprasit et al. 2026 | No significant differences in adverse events across all comparisons |
| 17 Zeng et al. 2021 | Comparable to placebo; lower than NSAIDs; adding to NSAIDs did not increase events |
| 18 Wan et al. 2022 | Curcuminoid formulations could alleviate some adverse events caused by NSAIDs |
| 20 Chen et al. 2025 | Adverse events comparable (RR 1.02, 95% CI 0.94–1.10) |
| 21 Sawangjit et al. 2025 | Mostly mild gastrointestinal symptoms, comparable to placebo |
| 24 Hsiao et al. 2021 | Higher AE rates with NSAIDs, significant in only one study |
6. What Remains Open: Limits of the Evidence
- Many studies are small and short, and form, curcuminoid content as well as duration of administration are often not precisely stated.
- Information on manufacturer funding is largely missing, which makes it difficult to assess the findings.
- The bioavailability of conventional curcumin is low; the absorption findings apply only to the specific form investigated in each case.
- Findings from mixed preparations with other polyphenols, Boswellia serrata or NSAIDs cannot be attributed to curcumin alone.
- It remains open which form and which curcuminoid content are effective for which endpoint.
7. Bottom Line: What Is Established About Turmeric and Curcumin
Turmeric and curcumin have been investigated in numerous controlled human studies and meta-analyses. Improvements are seen in metabolic and blood values, in inflammation-related complaints, in joint and movement complaints as well as in digestive complaints. Specially prepared forms such as micellar and water-soluble preparations increased the absorption of curcuminoids compared with conventional curcumin in small studies. Tolerability was good in most studies, although gastrointestinal side effects occurred more frequently in individual studies.
The validity is limited by the fact that many studies are small and short, form and curcuminoid content remain inconsistent and information on manufacturer funding is largely missing. Individual endpoints remained without difference, and a randomised controlled study in healthy older people found elevated blood glucose under curcumin. Findings from mixed preparations cannot be attributed to curcumin alone.
Frequently Asked Questions
How well has Turmeric and Curcumin been studied in humans?
We evaluated 375 human studies on Turmeric and Curcumin, including 242 randomised controlled trials and 101 meta-analyses or systematic reviews; the controlled studies include 16,291 participants in total. As of 4 October 2026.
Does Turmeric and Curcumin help with metabolism and blood values? What the studies show
Does Turmeric and Curcumin help with inflammation-related conditions? What the studies show
Does Turmeric and Curcumin help with joints and the musculoskeletal system? What the studies show
Does Turmeric and Curcumin help with absorption in the body? What the studies show
Does Turmeric and Curcumin help with digestion? What the studies show
Does Turmeric and Curcumin help with tolerability and safety? What the studies show
What is the difference between turmeric and curcumin?
Turmeric is the dried and ground rhizome of Curcuma longa, a plant from the ginger family. Curcumin is the yellow colouring of the rhizome and belongs to the group of curcuminoids. Turmeric traditionally serves as a spice and colouring agent.
Which forms of curcumin were investigated in the studies?
Ground turmeric rhizome powder, curcuminoid-rich extracts, curcumin with piperine from black pepper, curcumin in phytosome form as well as individual curcuminoids and hydrogenated curcumin were investigated. Some of the studies tested mixed preparations with other substances. The absorption findings apply only to the specific form investigated in each case.
How well is curcumin tolerated?
Several controlled studies and reviews described curcuminoids, curcumin in phytosome form and hydrogenated curcuminoids as well tolerated 8589159228279. Liver and kidney values remained unremarkable 110, the liver enzymes also under micellar curcuminoids 247. For gastrointestinal side effects, the picture was mixed, and due to the mostly short study duration, the findings can only be transferred to long-term use to a limited extent.
Why is the bioavailability of curcumin an issue?
Conventional curcumin is poorly absorbed; micellar and water-soluble preparations achieved significantly higher blood levels in small studies 278294299. These findings apply only to the specific form investigated in each case. Most of these studies were small and investigated healthy volunteers over a short period.
Can findings from mixed preparations be transferred to curcumin alone?
No. To make a statement about curcumin alone, studies with the individual substance are necessary.
Sources
- 1An P, Wan S, Luo Y, Luo J, Zhang X, Zhou S et al. · 2022
- 2Wang R, Huang K, Wang M, Zou W, Huang Y, Jiang W et al. · 2025
- 3Wan S, Luo J, Zhu Y, An P, Luo Y, Xing Q · 2024
- 4Jafari A, Abbastabar M, Alaghi A, Heshmati J, Crowe FL, Sepidarkish M · 2024
- 5Naghsh N, Musazadeh V, Nikpayam O, Kavyani Z, Moridpour AH, Golandam F et al. · 2023
- 6Zhang Y, Gui Y, Adams R, Farragher J, Itsiopoulos C, Bow K et al. · 2025
- 7Long Z, Xiang W, He Q, Xiao W, Wei H, Li H et al. · 2023
- 8Amgain K, Shah R, Md Noh SM, Shrestha S, Aryal B, Joshi LR et al. · 2025
- 9Gutsche LC, Dörfler J, Hübner J · 2025
- 10Zeng Y, He T, Ma X, Guo Q, Zhang J · 2025
- 11Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W et al. · 2022
- 12Zhao J, Liang G, Zhou G, Hong K, Yang W, Liu J et al. · 2024
- 13Ranneh Y, Bedir AS, Abu-Elsaoud AM, Al Raish S · 2024
- 14Del Grossi Moura M, Lopes LC, Biavatti MW, Kennedy SA, de Oliveira E Silva MC, Silva MT et al. · 2017
- 15Hsueh HC, Ho GR, Tzeng SI, Liang KH, Horng YS · 2025
- 16Inprasit C, Bunyamahote S, Boonpattharatthiti K, Thimkorn P, Intakhiao S, Dhippayom T · 2026
- 17Zeng L, Yu G, Hao W, Yang K, Yang K, Chen H · 2021
- 18Wan Y, Sun W, Yang J, Ren J, Kou Q · 2022
- 19Xie H, Zhang S, Meng Q, Wang Z, Zhu L, Xu W et al. · 2026
- 20Chen D, Yang J, Yang W, Liu X, Li Z · 2025
- 21Sawangjit R, Sadoyu S, Manosanthipaibul S, Teerawattanapong N, Puttarak P, Wanaratna K et al. · 2025
- 22Mokgalaboni K, Mashaba RG, Phoswa WN, Lebelo SL · 2024
- 23
- 24Hsiao AF, Lien YC, Tzeng IS, Liu CT, Chou SH, Horng YS · 2021
- 25Indriyani N, Nur'aeny N · 2025
- 26Yuan J, Pi C, Shen H, Zhou B, Wei Y, Dechsupa N et al. · 2025
- 27Gaffey A, Slater H, Porritt K, Campbell JM · 2017
- 28Shi W, Wang Q, Jiang S, Wu Y, Li C, Xie Y et al. · 2024
- 29Bannuru RR, Osani MC, Al-Eid F, Wang C · 2018
- 30Kheiridoost-Langaroodi H, Shakouri SK, Amirpour M, Iranshahi AM, Farshbaf-Khalili A · 2022
- 31Terby S, Shereef M, Ramanarayanan V, Balakrishnan B · 2021
- 32Wu D, Dong Y, Zhang D, Wang T, Ye H, Zhang W · 2025
- 33Mirzaei Dahka S, Afsharfar M, Tajaddod S, Sohouli MH, Shekari S, Bakhshi Nafouti F et al. · 2023
- 34Bahari H, Sharifi M, Nejad Shahrokh Abadi Z, Shahraki Jazinaki M, Golafrouz H, Asadi Z · 2026
- 35Zhang Y, Huang L, Zhang J, De Souza Rastelli AN, Yang J, Deng D · 2022
- 36Heuzeroth G, Kaufmann ME, Herter-Aeberli I, Schlagenauf U, Liu CC, Papageorgiou SN et al. · 2025
- 37Hidayat R, Parlindungan F, Nisa JI, Mahendra AI, Indika MI, Efendi C · 2025
- 38Brooks L, Farid AFBA, Poobalan A, Johnstone A, Myint PK · 2026
- 39
- 40Alivand N, Alivand S, Masoumi SJ, Foshati S, Abbasi E · 2026
- 41Santana DS, Porto BC, Cardoso RB, Lopes GMM, Gimenez LGS, Passerotti CC et al. · 2026
- 42Fang F, Qin D, Li Y, Liu F, Wu J · 2025
- 43
- 44Arabi SM, Mollahasni A, Azarian A, Chambari M, Bahrami LS, Sahebkar A · 2026
- 45Berkovitz S, Collaço N, Dolakova K, Hughes J · 2026
- 46Wang W, Zhao R, Liu B, Li K · 2025
- 47Ghoflchi S, Jalili-Nik M, Hashemy SI, Karav S, Hosseini H, Sahebkar A · 2026
- 48Marsh A, Quelch D, Mackonochie M, Hejmadi M, Rolfe V · 2024
- 49Tsai IC, Hsu CW, Chang CH, Tseng PT, Chang KV · 2021
- 50Ng QX, Koh SSH, Chan HW, Ho CYX · 2017
- 51Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS · 2018
- 52
- 53Fan Y, Yi Z, Mao S, Wen J, Zhang J, Zhang Q et al. · 2025
- 54Guo J, Xie H, Mao S, Liang M, Wu H · 2020
- 55Amatto PPG, Chaves L, França SC, Carvalho JCT, Carmona F, Pereira AMS · 2025
- 56Musazadeh V, Faghfouri AH, Falahatzadeh M, Mahmoudinezhad M, Alizadeh M, Shidfar F · 2026
- 57Sivamaruthi BS, Chaiyasut C, Kesika P · 2026
- 58Brodziński K, Juszczyńska J, Karbowska J, Kochan Z · 2026
- 59Rajabian F, Khajavi Rad A, Ghorban Sabbagh M, Hosseinzadeh H · 2026
- 60Mahapatro A, Jeanty H, Adla Jala SR, Priya Somu K, Madineni G, Mohanty E et al. · 2026
- 61
- 62Victoria-Montesinos D, Zafrilla P, Ballester P, García-Muñoz AM · 2026
- 63Alexandrova AS, Boyanov VS, Boyanova LY, Gergova RT · 2026
- 64Andrés CMC, Lastra JMP, Bustamante Munguira E, Juan CA, Lebeña EP · 2026
- 65Unhapipatpong C, Julanon N, Shantavasinkul PC, Polruang N, Numthavaj P, Thakkinstian A · 2025
- 66Hosseini H, Ghavidel F, Rajabian A, Homayouni-Tabrizi M, Majeed M, Sahebkar A · 2025
- 67Ebrahimzadeh A, Ebrahimzadeh A, Fooladshekan S, Mohseni S, Mohtashamian A, Babajafari S et al. · 2025
- 68Karimi M, Javadi M, Sharifi M, Valizadeh F, Karimi MA, Asbaghi O · 2025
- 69Mohammadi S, Ziaei S, Morvaridi M, Hasani M, Mirtaheri E, Farsi F et al. · 2025
- 70Rajabinasab F, Tabatabaei FSA, Kheirandish A, Hajimirzaei P, Abolfazli S, Aromolaran AS et al. · 2025
- 71Yu M, Liu S, Li J, Ni C, Li X, Cui W · 2025
- 72
- 73Al-Makhmari S, Al-Aufi A, Al-Kindi S, Alriyami M, Sakr H, Boulassel MR et al. · 2025
- 74Bahrami LS, Rahnama I, Chambari M, Norouzy A, Karav S, Arabi SM et al. · 2025
- 75Shrateh ON, Jawed A, Shuja MH, Kumar KA, Rehan ST, Abdelrhman S et al. · 2025
- 76Cherappurath N, Navaf M, Ceylan Hİ, Elayaraja M, Sunooj KV, Satheesan ST et al. · 2025
- 77Piekarz J, Picheta N, Pobideł J, Daniłowska K, Gil-Kulik P · 2025
- 78Parvizi MM, Arefkia A, Dehghan Y, Salimi MA, Fazelzadeh Haghighi N · 2025
- 79Sato BYS, Chong SI, Souza NMP, Lazo REL, Pontarolo R, Rego FGM et al. · 2025
- 80Bideshki MV, Jourabchi-Ghadim N, Radkhah N, Behzadi M, Asemani S, Jamilian P et al. · 2024
- 81
- 82Conti V, Polcaro G, De Bellis E, Donnarumma D, De Rosa F, Stefanelli B et al. · 2024
- 83Wu CF, Wu HJ, Shih CL, Yeh TP, Ma WF · 2024
- 84Kubizna M, Dawiec G, Wiench R · 2024
- 85Thavorn K, Wolfe D, Faust L, Shorr R, Akkawi M, Isaranuwatchai W et al. · 2024
- 86Widjanarko ND, Tamio E, Jusni LFJ, Alvianto S, Arifin ES, Iryaningrum MR · 2024
- 87Pathomwichaiwat T, Jinatongthai P, Prommasut N, Ampornwong K, Rattanavipanon W, Nathisuwan S et al. · 2023
- 88Diantini A, Febriyanti RM, Levita J · 2023
- 89de Waure C, Bertola C, Baccarini G, Chiavarini M, Mancuso C · 2023
- 90Safety and Efficacy of Turmeric (Curcuma longa) Extract and Curcumin Supplements in Musculoskeletal Health: A Systematic Review and Meta-AnalysisDoyle L, Desomayanandam P, Bhuvanendran A, Thanawala S, Shah R, Somepalli V et al. · 2023
- 91Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W et al. · 2022
- 92Saeedi F, Farkhondeh T, Roshanravan B, Amirabadizadeh A, Ashrafizadeh M, Samarghandian S · 2022
- 93Paultre K, Cade W, Hernandez D, Reynolds J, Greif D, Best TM · 2021
- 94Coelho MR, Romi MD, Ferreira DMTP, Zaltman C, Soares-Mota M · 2020
- 95Grammatikopoulou MG, Gkiouras K, Papageorgiou SΤ, Myrogiannis I, Mykoniatis I, Papamitsou T et al. · 2020
- 96Holleran G, Scaldaferri F, Gasbarrini A, Gasbarrini A, Currò D · 2020
- 97Letarouilly JG, Sanchez P, Nguyen Y, Sigaux J, Czernichow S, Flipo RM et al. · 2020
- 98
- 99Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ · 2018
- 100Liu X, Eyles J, McLachlan AJ, Mobasheri A · 2018
- 101
- 102Garg AX, Devereaux PJ, Hill A, Sood M, Aggarwal B, Dubois L et al. · 2018
- 103Takayama T, Okamoto K, Ishikawa H, Kagemoto K, Yasaka T, Hisabe T et al. · 2026
- 104Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C et al. · 2014
- 105Ahmad T, Khan I, Sultana A, Rizvi MMA · 2023
- 106Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S · 2024
- 107Hossaini Alhashemi S, Mohammadpour AH, Heidari R, Nikoo MH, Nemati MH, Vazin A · 2022
- 108
- 109Rudrappa GH, Murthy M, Saklecha S, Kumar Kare S, Gupta A, Basu I · 2022
- 110Yaikwawong M, Kamdee K, Chuengsamarn S · 2025
- 111Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S · 2024
- 112Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S · 2024
- 113Saghafi F, Zare P, Hatamizadeh N, Malmir M, Sahebnasagh A · 2025
- 114Chitre D, Nadkarni S, Jagtap N, Tulle R, Gitte A, Rahate P et al. · 2023
- 115Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A et al. · 2018
- 116Bhat SS, Ahmed S, Reji R, Mehta P, Paul A, Mohanan M et al. · 2023
- 117Prasad N, Vinay V, Srivastava A · 2023
- 118Derosa G, D'Angelo A, Vanelli A, Maffioli P · 2020
- 119Saleh Z, Asgari MR, Ghorbani R, Babamohamadi H · 2025
- 120
- 121Ferro Y, Pujia R, Mazza E, Lascala L, Lodari O, Maurotti S et al. · 2022
- 122Shep D, Khanwelkar C, Gade P, Karad S · 2020
- 123Thanawala S, Shah R, Alluri KV, Bhupathiraju K, Prasad N, Agarwal Y · 2025
- 124Ajami S, Hosseini SH, Babanouri N, Hashemi Z · 2025
- 125
- 126Wightman E, Khan J, Smith E, Rolfe V, Smith D, Young G et al. · 2023
- 127Libonati GA, Leone A, Martellucci S, Gallo A, Albera R, Lucisano S et al. · 2022
- 128Nikpour F, Ansari S, Abedi P, Jahanfar S, Sharifat N, Hooshmand G et al. · 2024
- 129Bahrami A, Jafari-Nozad AM, Karbasi S, Ayadilord M, Ferns GA · 2023
- 130Seyedabadi S, Hoseini ZS, Ferns GA, Bahrami A · 2023
- 131
- 132Purbadi S, Rustamadji P, Prijanti AR, Sekarutami SM, Sutrisna B, Suyatna FD et al. · 2020
- 133Goyal S, Beniwal SK, Agarwal P, Brar RK, Jain P, Kumar HS et al. · 2025
- 134Sadeghzadeh Z, Ostadrahimi A, Ranjbar M, Farshbaf-Khalili A · 2023
- 135Kheiridoost H, Shakouri SK, Shojaei-Zarghani S, Dolatkhah N, Farshbaf-Khalili A · 2022
- 136Farshbaf-Khalili A, Farajnia S, Pourzeinali S, Shakouri SK, Salehi-Pourmehr H · 2021
- 137Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M et al. · 2017
- 138Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M et al. · 2017
- 139Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A · 2015
- 140Yaikwawong M, Kamdee K, Chuengsamarn S · 2026
- 141Mamatha K, Prabhakaran P, Syam Das S, Kanjoormana Aryan M, Thomas J · 2025
- 142Karlapudi V, Prasad Mungara AVV, Sengupta K, Davis BA, Raychaudhuri SP · 2018
- 143Hu J, Fan D, Xiao C, Kang C, Shi J, Li Y et al. · 2026
- 144Alirezaei L, Golmohammadi H, Pourrashid MH, Kheiri AA, Sarbakhsh P, Samankan S et al. · 2025
- 145Majeed M, Nagabhushanam K, Devarajan TV, Saklecha S, Reddy SVK, Mundkur L · 2023
- 146Panahi Y, Khalili N, Sahebi E, Namazi S, Simental-Mendía LE, Majeed M et al. · 2018
- 147Panahi Y, Khalili N, Sahebi E, Namazi S, Atkin SL, Majeed M et al. · 2017
- 148Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A · 2014
- 149Nieman DC, Shanely RA, Luo B, Dew D, Meaney MP, Sha W · 2013
- 150Ariyasriwatana C, Phoolcharoen N, Oranratanaphan S, Worasethsin P · 2022
- 151Mansour A, Rahimi HR, Gerami H, Khorasanian AS, Esmaeili AH, Amrollahi Bioky A et al. · 2025
- 152Thanawala S, Shah R, Alluri KV, Bhupathiraju K, Salvi A · 2025
- 153Majumdar A, Prasad MAVV, Gandavarapu SR, Reddy KSK, Sureja V, Kheni D et al. · 2025
- 154
- 155Piyush P, Mahajan A, Singh K, Ghosh S, Gupta S · 2019
- 156Maulina T, Diana H, Cahyanto A, Amaliya A · 2018
- 157Sousa DF, Araújo MFM, de Mello VD, Damasceno MMC, Freitas RWJF · 2021
- 158
- 159Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A · 2015
- 160Rudrappa GH, Chakravarthi PT, Benny IR · 2020
- 161Messier H, D'Adamo CR, Panchal N, Patel G · 2026
- 162Azhdari M, Karandish M, Mozaffari-khosravi H, Cheraghian B, Mohammadi SM · 2026
- 163Yuan S, Liu X, Bracken K, Christensen R, Deveza LA, Collins S et al. · 2026
- 164Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M et al. · 2019
- 165Tehrani SD, Hosseini A, Shahzamani M, Heidari Z, Askari G, Majeed M et al. · 2024
- 166Karbasi S, Seyedabadi S, Mozaffari S, Foroutan Z, Ferns GA, Zarban A et al. · 2024
- 167Bahrami A, Mohammadifard M, Rajabi Z, Motahari-Nasab M, Ferns GA · 2022
- 168Mirhafez SR, Azimi-Nezhad M, Dehabeh M, Hariri M, Naderan RD, Movahedi A et al. · 2021
- 169Cicero AFG, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi C · 2020
- 170Cox KHM, White DJ, Pipingas A, Poorun K, Scholey A · 2020
- 171Khanna A, Das SS, Smina TP, Thomas JV, Kunnumakkara AB, Maliakel B et al. · 2020
- 172Derosa G, Catena G, Raddino R, Gaudio G, Maggi A, D'Angelo A et al. · 2018
- 173Mirhafez SR, Dehabeh M, Hariri M, Farimani AR, Movahedi A, Naderan RD et al. · 2021
- 174Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S · 2025
- 175Akbarzadeh F, Niksun N, Behravan G, Behdani F, Mohammadpour AH, Jaafari M et al. · 2023
- 176Viudes DR, Mateus AR, Silva CA, do Carmo Franco M · 2026
- 177Talebpour A, Mohammadifard M, Zare Feyzabadi R, Mahmoudzadeh S, Rezapour H, Saharkhiz M et al. · 2023
- 178Arabnezhad L, Mohammadifard M, Rahmani L, Majidi Z, Ferns GA, Bahrami A · 2022
- 179Hosseini H, Bagherniya M, Sahebkar A, Iraj B, Majeed M, Askari G · 2024
- 180Majeed M, Nagabhushanam K, Noureddin M, Paulose S, Barik C, Saklecha S et al. · 2023
- 181Tabaee S, Sahebkar A, Aghamohammadi T, Pakdel M, Dehabeh M, Sobhani R et al. · 2021
- 182Chen WT, Yang TS, Chen HC, Chen HH, Chiang HC, Lin TC et al. · 2014
- 183Neta JFF, Veras VS, Sousa DF, Cunha MDCDSO, Queiroz MVO, Neto JCGL et al. · 2021
- 184Zabihi M, Hoseinzadeh F, Mostafaei M, Vahedian-Ardakani HA, Saghafi F · 2026
- 185Somprajob C, Auychai P, Chavanavesh J, Suttamanatwong S · 2025
- 186Mogharrabi M, Rahimi HR, Hasanzadeh S, Dastani M, Kazemi-Oskuee R, Akhlaghi S et al. · 2020
- 187Panahi Y, Valizadegan G, Ahamdi N, Ganjali S, Majeed M, Sahebkar A · 2019
- 188Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Boqué N, Puiggrós F et al. · 2021
- 189Giacosa A, Riva A, Petrangolini G, Allegrini P, Fazia T, Bernardinelli L et al. · 2022
- 190Panahi Y, Saberi-Karimian M, Valizadeh O, Behnam B, Saadat A, Jamialahmadi T et al. · 2021
- 191Alikiaii B, Khatib N, Badpeyma M, Hasanzadeh E, Abbasi S, Amini S et al. · 2025
- 192Alidadi M, Sahebkar A, Eslami S, Vakilian F, Jarahi L, Alinezhad-Namaghi M et al. · 2021
- 193Cavanah AM, Robinson LA, Aguilar MM, Molaison EF, Greene MW, Roberts MD et al. · 2026
- 194
- 195Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M · 2015
- 196Arantes DAC, da Silva ACG, Freitas NMA, Lima EM, de Oliveira AC, Marreto RN et al. · 2021
- 197Shadnoush M, Zahedi H, Norouzy A, Sahebkar A, Sadeghi O, Najafi A et al. · 2020
- 198
- 199Amini S, Dehghani A, Sahebkar A, Iraj B, Rezaeian-Ramsheh A, Askari G et al. · 2026
- 200Askari MA, Golpour-Hamedani S, Khorvash F, Yegdaneh A, Vajdi M · 2026
- 201Kukushkina A, Rogovskii V, Zhilenkova O, Sadekov T, Melnikov M, Boyko A · 2026
- 202
- 203Laval J, Phipps KR, Brinet S, Fournier MC, Douillard B, Pham S et al. · 2026
- 204Shrutha SP, Havale R, Chowdary YV, Balkattu K, Siddanatham VS · 2025
- 205Amini S, Dehghani A, Sahebkar A, Iraj B, Rezaeian-Ramsheh A, Askari G et al. · 2024
- 206
- 207
- 208Jaturapisanukul S, Kurathong S, Ngamvichchukorn T, Trakarnvanich T · 2022
- 209Ahmadi R, Salari S, Sharifi MD, Reihani H, Rostamiani MB, Behmadi M et al. · 2021
- 210Neetha MC, Panchaksharappa MG, Pattabhiramasastry S, Shivaprasad NV, Venkatesh UG · 2020
- 211Heidari-Beni M, Moravejolahkami AR, Gorgian P, Askari G, Tarrahi MJ, Bahreini-Esfahani N · 2020
- 212Phoolcharoen N, Oranratanaphan S, Ariyasriwatana C, Worasethsin P · 2019
- 213Saran G, Umapathy D, Misra N, Channaiah SG, Singh P, Srivastava S et al. · 2018
- 214Pandaran Sudheeran S, Jacob D, Natinga Mulakal J, Gopinathan Nair G, Maliakel A, Maliakel B et al. · 2016
- 215da Paz Martins AS, de Araújo ORP, da Silva Gomes A, Araujo FLC, Júnior JO, de Vasconcelos JKG et al. · 2025
- 216Bourbour F, Mahdavi B, Naghshi N, Yari Z, Hosseini SM, Kalbasi S et al. · 2026
- 217Bourbour F, Mahdavi B, Naghshi N, Yari Z, Hosseini SM, Kalbasi S et al. · 2026
- 218Kia SJ, Basirat M, Mortezaie T, Moosavi MS · 2020
- 219Boshagh K, Khorvash F, Sahebkar A, Majeed M, Bahreini N, Askari G et al. · 2023
- 220Gerami H, Mozaffari-Khosravi H, Mansour A, Sohrabpour AA, Poustchi H, Hashemi Taheri AP et al. · 2025
- 221Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, Salehizadeh L, Rahmani S, Behnam B et al. · 2020
- 222Mirhafez SR, Farimani AR, Gholami A, Hooshmand E, Tavallaie S, Nobakht M Gh BF · 2019
- 223Rooprai HK, Lawrence P, Ashkan K, Beaney R, Pilkington GJ, Gullan RW · 2026
- 224Musso G, Pinach S, Mariano F, Saba F, De Michieli F, Framarin L et al. · 2025
- 225
- 226Musso G, Alberto M, Mariano F, Cassader M, De Michieli F, Riva A et al. · 2024
- 227Tajdini A, Karimi Yazdi A, Ravand H, Sahebi L · 2023
- 228Gonzalez-Pons M, Dominguez RL, Montalvan-Sanchez EE, Foster NR, Strand CA, Hernandez-Marrero J et al. · 2026
- 229
- 230Hellou E, Mohsin J, Elemy A, Hakim F, Mustafa-Hellou M, Hamoud S · 2022
- 231
- 232Panda SK, Nirvanashetty S, Parachur VA, Mohanty N, Swain T · 2018
- 233Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S et al. · 2015
- 234Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T et al. · 2014
- 235Reis DCMV, Alvarenga L, Cardozo LFMF, Baptista BG, Fanton S, Paiva BR et al. · 2024
- 236Safety of NR-INF-02, an Extract of Curcuma Longa Containing Turmerosaccharides, in Healthy Volunteers: A Randomized, Open-label Clinical TrialSelvi M, Mohan Mv R, Bethapudi B, Mundkinajeddu D, Kumari S · 2022
- 237Pecoraro L, Zoller T, Atkinson RL, Nisi F, Antoniazzi F, Cavarzere P et al. · 2022
- 238Herrick LP, Goh J, Menke W, Campbell MS, Fleenor BS, Abel MG et al. · 2020
- 239Kalhori A, Rafraf M, Navekar R, Ghaffari A, Jafarabadi MA · 2022
- 240Askari G, Sahebkar A, Soleimani D, Mahdavi A, Rafiee S, Majeed M et al. · 2022
- 241Wahono CS, Susianti H, Hakim AL, Rosita F, Pratama MZ, Rahman PA et al. · 2024
- 242Schönenberger KA, Laval J, Woods T, Truillet R, Naranjo-Modad S, Mettler S et al. · 2025
- 243Gómez-Téllez A, Sierra-Puente D, Muñoz-Gómez R, Ibarra-Pitts A, Guevara-Cruz M, Hernández-Ortega M et al. · 2020
- 244Soltani M, Hosseinzadeh-Attar MJ, Rezaei M, Alipoor E, Vasheghani-Farahani A, Yaseri M et al. · 2024
- 245Lustberg M, Fan-Havard P, Wong FL, Hill K, Phelps MA, Herrera KW et al. · 2024
- 246Rezaei M, Soltani M, Alipoor E, Rezayat SM, Vasheghani-Farahani A, Yaseri M et al. · 2024
- 247Kocher A, Bohnert L, Schiborr C, Frank J · 2016
- 248Buntoonprayuk J, Chattrakulchai K, Vallibhakara O, Prasanchit P, Vallibhakara SA · 2026
- 249Singh S, Alok A, Shahnawaz K, Kumar S, Ramdas Naik S, Piyush K · 2026
- 250Gupta S, Jyothi SG, Siddiqui A, Dhanai A, Yadav H, Singh U · 2025
- 251Kapil D, Bari A, Sharma N, Velpandian T, Sinha R, Maharana P et al. · 2025
- 252Gharakhanlou BJ, Bonab SB, Amaghani A, Shiri-Shahsavar MR · 2025
- 253Doostkam A, Iravani K, Malekmakan L, Gholamabbas G, Roozbeh J, Soltaniesmaeili A · 2024
- 254Askari G, Bagherniya M, Kiani Z, Alikiaii B, Mirjalili M, Shojaei M et al. · 2023
- 255Hidayat YM, Wagey F, Suardi D, Susanto H, Laihad BJ, Tobing MDL · 2021
- 256Murillo Ortiz BO, Fuentes Preciado AR, Ramírez Emiliano J, Martínez Garza S, Ramos Rodríguez E, de Alba Macías LA · 2019
- 257The effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina: A randomized clinical trialDastani M, Bigdelu L, Hoseinzadeh M, Rahimi HR, Karimani A, Hooshang Mohammadpour A et al. · 2019
- 258Cicero AFG, Fogacci F, Morbini M, Colletti A, Bove M, Veronesi M et al. · 2017
- 259Panahi Y, Alishiri GH, Parvin S, Sahebkar A · 2016
- 260Rahimnia AR, Panahi Y, Alishiri G, Sharafi M, Sahebkar A · 2015
- 261Santos-Parker JR, Strahler TR, Bassett CJ, Bispham NZ, Chonchol MB, Seals DR · 2017
- 262Britto I, Couto H, de Paiva BR, de Brito JS, Alvarenga L, Cardozo LFMF et al. · 2025
- 263Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M et al. · 2012
- 264Macis D, Briata IM, D'Ecclesiis O, Johansson H, Aristarco V, Buttiron Webber T et al. · 2023
- 265Kattah FM, Figueiredo N, Bezerra KK, Oliveira ES, Melo CC, Lima GB et al. · 2025
- 266Alvarenga L, Salarolli R, Cardozo LFMF, Santos RS, de Brito JS, Kemp JA et al. · 2020
- 267Durham L, Oster RA, Ithurburn M, Reynolds C, Hill JO, Smith DL · 2026
- 268Thangeswaran S, S N, Maniangat Luke A, Ingafou MSH · 2026
- 269Ramalingam K, Dorairaj J, Saminathan S, Ravi S, Ravindran S, Desingu V · 2025
- 270Saberi-Karimian M, Orooji A, Taghizadeh N, Ekhteraee Toosi MS, Ferns GA, Aghasizadeh M et al. · 2023
- 271Fança-Berthon P, Tenon M, Bouter-Banon SL, Manfré A, Maudet C, Dion A et al. · 2021
- 272
- 273Effects of a Cinnamon, Curcumin/Turmeric Dietary Supplement on Glucose, Lipid, and Cognitive MeasuresYoung H, Clayton D, Masis N, Gaylor C, Benton D · 2020
- 274Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Walter H et al. · 2019
- 275Tuntiyatorn P, Lerspongpaibool C, Kanchanathepsak T, Watcharananan I, Tawonsawatruk T · 2025
- 276Santosa D, Rizqi DM, Pangarsa EA, Setiawan B, Suyono S, Tobing ML et al. · 2025
- 277Hellmann PH, Bagger JI, Carlander KR, Hansen KB, Forman JL, Størling J et al. · 2023
- 278Kothaplly S, Alukapally S, Nagula N, Maddela R · 2022
- 279Jacob J, Amalraj A, Raj KKJ, Divya C, Kunnumakkara AB, Gopi S · 2019
- 280Cardaci TD, Machek SB, Wilburn DT, Hwang PS, Willoughby DS · 2021
- 281Campbell MS, Ouyang A, I M K, Charnigo RJ, Westgate PM, Fleenor BS · 2019
- 282van Die MD, Williams SG, Emery J, Bone KM, Taylor JM, Lusk E et al. · 2017
- 283Efficacy of topical curcuma longa in the healing of extraction sockets: A split-mouth clinical trialPandya K, Abbinayah D, Selvakumar D, Jayakumar N · 2023
- 284Khan S, Arif M, Laraib H, Naqvi SN, Shah OA, Farooq U et al. · 2024
- 285Thambamroong T, Seetalarom K, Saichaemchan S, Pumsutas Y, Prasongsook N · 2022
- 286Donovan EK, Kekes-Szabo S, Lin JC, Massey RL, Cobb JD, Hodgin KS et al. · 2021
- 287Drobnic F, Riera J, Appendino G, Togni S, Franceschi F, Valle X et al. · 2014
- 288Kumar NB, Schabath M, Alexandrow M, Gray J, Tanventyanon T, Khalil F et al. · 2026
- 289Kumar NB, Schabath M, Alexandrow M, Gray J, Tanventyanon T, Khalil F et al. · 2026
- 290Kim DS, Kim HK, Ha KC, Jang GH, Park SH, Kim DH et al. · 2026
- 291van den Belt M, JanssenDuijghuijsen L, Tomassen M, de Roos N, Witteman B, Fança-Berthon P et al. · 2026
- 292Comparative Pharmacokinetics of Curcuminoids from Water-Dispersible Turmeric Extract Against a Curcuminoids-Piperine Combination: An Open-Label, Randomized, Balanced, 2-Treatment, 2-Sequence, 2-Period Crossover StudyThanawala S, Shah R, Doyle L, Upadhyay V · 2024
- 293Miranda-Castro S, Aidar FJ, de Moura SS, Marcucci-Barbosa L, Lobo LF, de Assis Dias Martins-Júnior F et al. · 2022
- 294Grafeneder J, Derhaschnig U, Eskandary F, Buchtele N, Sus N, Frank J et al. · 2022
- 295Rahalkar A, Kumathalli K, Kumar R · 2021
- 296Malhotra VK, Deshpande AC, Tamoli S, Soman GS, Sabnis Shinde R, Soman AD · 2025
- 297Thanawala S, Shah R, Alluri KV, Somepalli V, Vaze S, Upadhyay V · 2021
- 298McFarlin BK, Hill DW, Vingren JL, Curtis JH, Tanner EA · 2021
- 299Jabur L, Pandey R, Mikhael M, Niedermayer G, Gyengesi E, Mahns D et al. · 2025
- 300
- 301Wagner T, Wacker R, Klein T, Kompek A, Schön C · 2024
- 302Alvarenga L, Cardozo L, Schultz J, Modolon F, Rosado A, Mafra D · 2026
- 303
- 304
- 305Gomes TLN, Zenha RSS, Antunes AH, Faria FR, Rezende KR, de Souza EL et al. · 2021
- 306Messier H, Patel J, Bhomia V, Kataria D, Patel G · 2026
- 307Ghazaee H, Sahebkar A, Mazloum Khorasani Z, Emadzadeh M · 2026
- 308
- 309Srivastava A, Vinay V, Singh MK · 2026
- 310Abdoli S, Khazaei S, Mehrpooya M, Kazemi F, Jenabi E, Yazdaniroshan R · 2025
- 311Schönenberger KA, Ranzini C, Laval J, Bellenger P, Tenon M, Fança-Berthon P · 2025
- 312Cai T, Tamanini I, Puglisi M, Bizzotto L, Rizzo M, Liguori G et al. · 2024
- 313Pereira CH, Martins AFL, Morais MO, de Sousa-Neto SS, da Silva ACG, Arantes DAC et al. · 2024
- 314Erol Doğan Ö, Karaca Çelik KE, Baş M, Alan EH, Çağın YF · 2024
- 315Martins ASDP, Araújo ORP, Gomes ADS, Araujo FLC, Oliveira Junior J, Vasconcelos JKG et al. · 2024
- 316Uchio R, Okuda-Hanafusa C, Sakaguchi H, Saji R, Muroyama K, Murosaki S et al. · 2024
- 317Boeri L, De Lorenzis E, Lucignani G, Turetti M, Silvani C, Zanetti SP et al. · 2024
- 318Thorley J, Alhebshi A, Rodriguez-Mateos A, Zhang Z, Bailey SJ, Martin NRW et al. · 2024
- 319Singla R, Gupta C, Gill GS, Jain N, Arora S, Algarni YA et al. · 2024
- 320Martins ASdP, Araújo ORPd, Gomes AdS, Araujo FLC, Oliveira Junior J, Vasconcelos JKGd et al. · 2024
- 321Montalvan-Sanchez EE, Hernandez-Marrero J, Norwood DA, González-Pons M, Dominguez RL, Rodriguez LM et al. · 2024
- 322Ramos-Junior OJF, Pinheiro VDS, Souza TGDS, Alvares TS · 2024
- 323Wang Z, Winzenberg T, Singh A, Aitken D, Blizzard L, Boesen M et al. · 2023
- 324Sharifi S, Bagherniya M, Khoram Z, Ebrahimi Varzaneh A, Atkin SL, Jamialahmadi T et al. · 2023
- 325Martins AFL, Pereira CH, Morais MO, de Sousa-Neto SS, Valadares MC, Freitas NMA et al. · 2023
- 326Alvarenga L, Cardozo LFMF, Ribeiro-Alves M, Damasceno NRT, Berretta AA, Lima JA et al. · 2023
- 327Safari Z, Bagherniya M, Khoram Z, Ebrahimi Varzaneh A, Heidari Z, Sahebkar A et al. · 2023
- 328D'Orio M, De Vitis R, Taccardo G, Rocchi L, Ferrari F, Perna A et al. · 2023
- 329Jain A, Singh V, Lukram A, Chatterjee S, Khan AM, Dawar G · 2022
- 330Freitas E Silva-Santana NC, Rodrigues HCN, Pereira Martins TF, Braga CC, Silva MAC, Carlos da Cunha L et al. · 2022
- 331Ahmed Nasef N, Thota RN, Mutukumira AN, Rutherfurd-Markwick K, Dickens M, Gopal P et al. · 2022
- 332Aguilera EC, Vachon A, Plourde M · 2022
- 333Thanawala S, Shah R, Somepalli V, Alluri KV, Desomayanandam P, Bhuvanendran A · 2021
- 334Bahrami A, Zarban A, Rezapour H, Agha Amini Fashami A, Ferns GA · 2021
- 335Pawar KS, Mastud RN, Pawar SK, Pawar SS, Bhoite RR, Bhoite RR et al. · 2021
- 336Singhal S, Hasan N, Nirmal K, Chawla R, Chawla S, Kalra BS et al. · 2021
- 337Liu X, Robbins S, Eyles J, Fedorova T, Virk S, Deveza LA et al. · 2021
- 338Thota RN, Rosato JI, Dias CB, Burrows TL, Martins RN, Garg ML · 2020
- 339Manarin G, Anderson D, Silva JME, Coppede JDS, Roxo-Junior P, Pereira AMS et al. · 2019
- 340Fadinie W, Lelo A, Wijaya DW, Lumbanraja SN · 2019
- 341Peterson CT, Vaughn AR, Sharma V, Chopra D, Mills PJ, Peterson SN et al. · 2018
- 342Asher GN, Xie Y, Moaddel R, Sanghvi M, Dossou KS, Kashuba AD et al. · 2017
- 343Merolla G, Dellabiancia F, Ingardia A, Paladini P, Porcellini G · 2015
- 344Stancioiu F, Mihai D, Papadakis GZ, Tsatsakis A, Spandidos DA, Badiu C · 2019
- 345Deane CS, Din USU, Sian TS, Smith K, Gates A, Lund JN et al. · 2022
- 346Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N et al. · 2015
- 347Appelboom T, Maes N, Albert A · 2014
- 348Henrotin Y, Dierckxsens Y, Delisse G, Seidel L, Albert A · 2021
- 349Bonucci M, Fuggetta MP, Anelli L, Giannarelli D, Fiorentini C, Ravagnan G · 2025
- 350Pastorelli D, Fabricio ASC, Giovanis P, D'Ippolito S, Fiduccia P, Soldà C et al. · 2018
- 351Gbolahan OB, O'Neil BH, McRee AJ, Sanoff HK, Fallon JK, Smith PC et al. · 2022
- 352Pramvichai C, Mongkolwat W, Aluksanasuwan S, Jaidee W, Charoensup R, Pimtong S et al. · 2026
- 353Khan A, Rabbani F, Mumtaz SU, Javed R, Ujjan I, Kanwal A et al. · 2026
- 354Tuyaerts S, Rombauts K, Everaert T, Van Nuffel AMT, Amant F · 2018
- 355Osei-Bonsu GA, Dimick MK, Kennedy KG, Barton JS, Sultan AA, Young LT et al. · 2026
- 356Wang Q, Jiang K, Lan X, Zhang L, Duan Y, Gao J et al. · 2026
- 357Sanlier NT, Sacinti KG, Turkoglu İ, Sanlier N · 2026
- 358
- 359Caputo C, De Maio AC, Lombardi A, Sperlongano R, Caraglia M, Cautela D · 2026
- 360
- 361Sivamaruthi BS, Suganthy N, Chaiyasut C, Khongtan S, Fukngoen P, Kesika P · 2026
- 362Chen Y, Zhang X, Zeng R · 2026
- 363Arjona-Ruiz C, Valdez-Morales EE, Guerrero-Alba R · 2026
- 364
- 365Talath S, El-Tanani M, Wali AF, Rabbani SA, Bhongande B, Ibraheem W et al. · 2026
- 366Bashir S, Shah IM, Javeed S, Rafiquee A, Mir B, Hassan Mir R et al. · 2026
- 367Farzana HR, Vigriawan GE, Santini A, Nurkolis F · 2026
- 368Phytochemicals from medicinal plants as alternative therapeutics for metabolic syndrome: A review of randomized controlled trialsRad MS, Jamialahmadi T, Kesharwani P, Sahebkar A · 2025
- 369Konaktchieva M, Stojchevski R, Hadzi-Petrushev N, Gagov H, Konakchieva R, Mitrokhin V et al. · 2025
- 370
- 371Herbal Medicines in Autism Spectrum Disorder: Therapeutic Potential, Plant Components, and Dosage GuidelinesAldekhail NM, Khojah H, Alsaadoun NH, Al-Sanea MM, Alshammari SB, Alhazeemi AH et al. · 2025
- 372Gopalarathinam R, Sankar R, Zhao SS · 2024
- 373Gagliardi S, Morasso C, Stivaktakis P, Pandini C, Tinelli V, Tsatsakis A et al. · 2020
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.